Ipsen contributed royalties to Exelixis's collaboration revenues following the launch of CABOMETYX for NETs.
2 reports, 2 independent
Updated Jul 29
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 3
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Ipsen contributed royalties to Exelixis's collaboration revenues following the launch of CABOMETYX for NETs.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Cabometyx drove strong financial results for Exelixis in July 2025.Sub-event
Ipsen pays royalties to Exelixis for collaboration revenue from CABOMETYX launched in NETs.1 source
Exelixis is seeing sales success from the CABOMETYX launch.1 source
Keep exploring
The entities involved
-
Ipsen
company in Barcelona, Spain
Nothing else this week.
-
Exelixis
American biotechnology company
Nothing else this week.
Related events
Coverage
Newest first; wire copies grouped- GuruFocus.comExelixis Inc (EXEL) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Challenges Total Revenue: Approximately $568 million for Q2 2025. Cabozantinib Franchise Net Product Revenue:
- ZacksExelixis' Q2 Earnings: Will Cabometyx Sales Drive Growth? Investors will focus on lead drug Cabometyx’ performance when Exelixis (EXEL) reports second-quarter 2025 results on July 28. The Zacks Conse